Katarzyna Baron-Fross
Uppsala, C, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients.
Journal: Journal of neuroendocrinology
Published: November 12, 2023
Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT.
Journal: EJNMMI research
Published: July 15, 2021
Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.
Journal: Endocrine connections
Published: January 16, 2021
In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 05, 2019
177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.
Journal: Neuroendocrinology
Published: September 19, 2019
Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients.
Journal: Frontiers in oncology
Published: September 04, 2019
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE.
Journal: Cancers
Published: June 10, 2019
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.
Journal: European journal of nuclear medicine and molecular imaging
Published: September 29, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026